Carter Gould
Stock Analyst at Cantor Fitzgerald
(2.97)
# 1,211
Out of 4,829 analysts
208
Total ratings
66.67%
Success rate
23.82%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $535 | $439.37 | +21.77% | 3 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $48.18 | +14.16% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $575.63 | +20.74% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $23.09 | +3.94% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $31.59 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $80.43 | +5.68% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $755.57 | +29.04% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $103.82 | +20.40% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $190.07 | +10.49% | 15 | Apr 22, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $120.43 | +37.01% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.54 | -7.15% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $124.40 | +44.69% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $300 → $315 | $274.76 | +14.65% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $73.63 | +35.81% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.17 | +1,639.13% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.93 | +222.58% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.28 | +603.13% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $32.13 | +195.67% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $20.66 | -3.19% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $59.46 | +22.78% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.33 | +203.40% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.20 | +900.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.10 | +36.36% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.46 | +386.38% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $258.38 | +47.07% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $60.85 | +34.76% | 5 | Jan 16, 2019 |
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: $535
Current: $439.37
Upside: +21.77%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $48.18
Upside: +14.16%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $575.63
Upside: +20.74%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $23.09
Upside: +3.94%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.59
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $80.43
Upside: +5.68%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $755.57
Upside: +29.04%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $103.82
Upside: +20.40%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $190.07
Upside: +10.49%
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $120.43
Upside: +37.01%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $21.54
Upside: -7.15%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $124.40
Upside: +44.69%
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $274.76
Upside: +14.65%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $73.63
Upside: +35.81%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.17
Upside: +1,639.13%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.93
Upside: +222.58%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.28
Upside: +603.13%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $32.13
Upside: +195.67%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $20.66
Upside: -3.19%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $59.46
Upside: +22.78%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.33
Upside: +203.40%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.20
Upside: +900.00%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.10
Upside: +36.36%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.46
Upside: +386.38%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $258.38
Upside: +47.07%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $60.85
Upside: +34.76%